West Pharmaceutical Services, Inc. (WST)
| Market Cap | 15.77B |
| Revenue (ttm) | 2.90B |
| Net Income (ttm) | 467.20M |
| Shares Out | 71.85M |
| EPS (ttm) | 6.37 |
| PE Ratio | 34.43 |
| Forward PE | 34.48 |
| Dividend | $0.84 (0.38%) |
| Ex-Dividend Date | Jul 30, 2025 |
| Volume | 666,001 |
| Open | 218.25 |
| Previous Close | 213.06 |
| Day's Range | 214.67 - 220.94 |
| 52-Week Range | 187.43 - 372.79 |
| Beta | 1.14 |
| Analysts | Strong Buy |
| Price Target | 349.00 (+59.03%) |
| Earnings Date | Apr 24, 2025 |
About WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhanc... [Read more]
Financial Performance
In 2024, WST's revenue was $2.89 billion, a decrease of -1.92% compared to the previous year's $2.95 billion. Earnings were $492.70 million, a decrease of -16.97%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for WST stock is "Strong Buy." The 12-month stock price forecast is $349.0, which is an increase of 59.03% from the latest price.
News
West to Participate in Upcoming Investor Conferences
EXTON, Pa. , May 7, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will prese...
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against West Pharmaceutical Services, Inc. (WST)
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pen...
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...
West Pharmaceutical Defies Doubters: EPS Jumps, Outlook Raised Despite Tariff Drag
West Pharmaceutical Services, Inc. WST on Thursday reported first-quarter 2025 adjusted EPS of $1.45, beating the consensus of $1.23.
West Pharmaceutical Services, Inc. (WST) Q1 2025 Earnings Call Transcript
West Pharmaceutical Services, Inc. (NYSE:WST) Q1 2025 Earnings Conference Call April 24, 2025 9:00 AM ET Company Participants John Sweeney - Vice President of Investor Relations Eric Green - Chairman...
West Pharma raises profit forecast as dollar weakens amid Trump's tariff policies
West Pharmaceutical Services raised its annual profit forecast on Thursday, anticipating a boost from a weaker dollar to shield it from a potential hit from U.S. President Donald Trump's tariffs.
West Announces Leadership Changes
Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa. , Apri...
West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.
West to Host First-Quarter 2025 Conference Call
EXTON, Pa. , April 10, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will rel...
Best Dividend Aristocrats For April 2025
Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Br...
Buy 2 March S&P 500 Dividend Aristocrats Out Of 37 'Safer'
Four of the ten lowest-priced Dividend Aristocrats, including Franklin Resources and Realty Income, are ready to buy with annual dividends exceeding their single share prices. Analysts forecast 15.93%...
West Pharmaceutical: Remains A Strong Long-Term Prospect
West Pharmaceutical Services has faced a challenging year, underperforming against the index, with declining volumes, margins, and returns, but remains a strong long-term investment. The company's hig...
Top 2 Health Care Stocks That May Rocket Higher This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
West Announces Second-Quarter Dividend
EXTON, Pa. , Feb. 20, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company...